HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SBFM
Sunshine Biopharma, Inc.
There isn't enough reported data to score SBFM yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SBFM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Unavailable |
SBFM's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SBFM PE Valuation
SBFM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SBFM Forward outlook
There aren't enough analyst estimates for SBFM to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SBFM Earnings Per Share
SBFM and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SBFM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SBFM on profitability, with a higher operating margin.
SBFM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.4M | +0.3% |
| Q2 2026 | $9.3M | -1.6% |
| Q1 2026 | $8.1M | -9.1% |
| Q4 2025 | $8.6M | -11% |
| Q3 2025 | $9.4M | +12% |
| Q2 2025 | $9.4M | +1.2% |
| Q1 2025 | $8.9M | +18% |
| Q4 2024 | $9.6M | +25% |
SBFM's revenue is down over the past year, though its latest quarter was up: $9M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -2.1 points |
| Q2 2026 | -17% | +4.4 points |
| Q1 2026 | -17% | -2.7 points |
| Q4 2025 | -21% | +0.4 points |
| Q3 2025 | -12% | +1.6 points |
| Q2 2025 | -22% | -8.2 points |
| Q1 2025 | -15% | +3.3 points |
| Q4 2024 | -21% | -5.8 points |
SBFM's operating margin was −14% last quarter, down 2.1 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SBFM on cash generation, producing positive trailing cash flow while its opponent burns cash.
SBFM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | -$648.2K |
| Q2 2026 | -$925K | +$508.4K |
| Q1 2026 | -$2.1M | -$355.9K |
| Q4 2025 | -$1.6M | +$1.9M |
| Q2 2025 | -$1.4M | +$3.1M |
| Q1 2025 | -$1.7M | +$1.5M |
| Q4 2024 | -$3.5M | -$1.2M |
| Q1 2024 | -$3.2M | -$1.3M |
SBFM has burned cash in almost every quarter: −$6M over the past year, against −$7M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SBFM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SBFM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +178% | +43.7K shares |
| 1 year | +279% | +50.2K shares |
SBFM has 68,266 diluted shares, up 279% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SBFM Net Leverage
SBFM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SBFM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 19.1 | Oversold |
| Stochastic | 0.9 | Oversold |
SBFM's weekly RSI is 19 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SBFM PE vs Healthcare Sector
SBFM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SBFM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.61 | 57% below |
| 20 week MA | $19.3 | 85% below |
| 50 week MA | $123.0 | 98% below |
| 100 week MA | $245.6 | 99% below |
| 200 week MA | $59,597.2 | 100% below |
SBFM is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SBFM on returns for 2026, with the stronger performance.
SBFM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $200,000.0 | $334,000.0 | +67% |
| 2021 | $334,000.0 | $1,298,000.0 | +289% |
| 2022 | $1,298,000.0 | $264,000.0 | -80% |
| 2023 | $264,000.0 | $108,600.0 | -59% |
| 2024 | $108,600.0 | $612.0 | -99% |
| 2025 | $612.0 | $252.0 | -59% |
| 2026 YTD | $252.0 | $2.84 | -99% |
SBFM has finished four years in a row lower, and it's down 99% so far in 2026.